Generic Drug Development CDMO

Introduction Contract Development and Manufacturing Organizations (CDMOs) implement ICH Q2(R2) and ICH Q14 as an integrated, lifecycle-oriented framework that brings […]

Introduction CDMO Quality Agreements function as legally binding quality management frameworks established under Current Good Manufacturing Practice (CGMP) regulations to

Introduction Analytical Method Transfer Between CDMO Sites is a formal and documented process used to qualify a receiving Contract Development

Introduction Phase-Appropriate CMC Development at a CDMO represents a risk-managed approach to scaling that aligns Chemistry, Manufacturing, and Controls activities

Introduction: FDA Sameness for Complex Generic Drugs is a scientific and regulatory assessment used to determine whether a proposed generic

Introduction: Technology Transfer to GMP CDMO is one of the most technically demanding steps in bringing a first-in-generic modified-release tablet

Introduction A peptide purity testing report, commonly presented as a Certificate of Analysis (CoA) or analytical datasheet, is a critical

Introduction When a Complete Response Letter (CRL) is issued for a Generic ANDA under 21 CFR 314.110, the applicant immediately

Introduction The choice between the 505(b)(2) vs ANDA Regulatory Pathway depends largely on whether the proposed drug product is an

Introduction Pharmaceutical sponsors can execute a Switch CDMO After ANDA Submission, but the regulatory approach depends on whether the ANDA